Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for the purchase and sale of common stock and warrants.
The offering is expected to result in gross proceeds of approximately $4.0 million before deducting fees and expenses.
The net proceeds from the offering will be used for working capital and general corporate purposes.
Offering Details
1,033,591 shares of common stock (or common stock equivalents) and warrants for up to 2,067,182 shares at $3.87 per share.
Closing Date
Expected to occur on or about December 31, 2025, subject to customary closing conditions.
Placement Agent
Curvature Securities LLC is the sole placement agent for the offering.
- The offering provides Glucotrack, Inc. with additional funding for operational needs and growth opportunities.
- The securities are issued in reliance on exemptions under the Securities Act, with plans for a registration statement for resale.
Glucotrack, Inc.'s successful private placement announcement signifies a strategic move to enhance financial stability and support growth initiatives in the medical technology sector.